Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
TEL AVIV, Israel – PainReform Ltd., a pharmaceutical company specializing in preparations for pain relief, announced today that it will hold an Extraordinary General Meeting of Shareholders on August 13, 2024. The meeting is scheduled for 3:00 p.m. local time at the offices of the Company's legal counsel in Bnei Brak, Israel.
The purpose of the gathering is for shareholders to vote on undisclosed proposals detailed in the Notice and Proxy Statement provided by the company. Shareholders have the option to vote in person or by proxy, with the company facilitating the latter through a Proxy Card system.
The documentation related to the meeting, including the Notice and Proxy Statement and the Proxy Card, has been made available as part of the company's recent filing with the U.S. Securities and Exchange Commission (SEC). These materials contain comprehensive information on the voting procedures and the matters up for consideration at the meeting.
PainReform Ltd., listed under the SEC file number 001-39481, is incorporated in Israel and operates out of its headquarters in Tel Aviv. As a foreign private issuer, PainReform files annual reports using Form 20-F, adhering to the regulations set forth by the SEC.
The notification of this meeting comes as a routine aspect of corporate governance, allowing shareholders to have a direct influence on the company's strategic decisions. PainReform's interim CEO, Ehud Geller, signed off on the report, underscoring the importance of shareholder engagement in the company's operations.
In other recent news, Teva Pharmaceutical Industries (NYSE:TEVA) Ltd. has settled a longstanding tax dispute with the Israeli Tax Authority by agreeing to a payment of $750 million, to be made from 2024 to 2029. The company has also launched the first generic version of the diabetes drug Victoza, providing a more affordable option for patients and healthcare providers. Teva has initiated an antitrust lawsuit against Corcept Therapeutics (NASDAQ:CORT), alleging a monopoly over the Korlym market, a treatment for Cushing's syndrome.
Analysts from Piper Sandler and Barclays have maintained an Overweight rating on Teva shares. Teva is implicated in opioid crisis settlements exceeding $46 billion. Lastly, Teva has appointed Matthew Shields as the Executive Vice President of Teva Global Operations. Teva has also presented a new sub-analysis from its PEARL study suggesting that pauses in migraine prevention treatment could lead to increased migraine days and reduced effectiveness upon treatment reinitiation. These are the recent developments involving Teva Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.